Prostate cancer is the second most common cancer in men, and rates are on the rise. By 2030 there’ll be 1.7 million men living with prostate cancer. It’s already killing hundreds of thousands of men each year, and those who survive face serious side effects.
We can’t afford to let this continue.
So we’re taking action.
We’ve spent years learning how to tackle the toughest cancer challenges in innovative ways. Now it's time to draw a line in the sand.
By 2030 we’ll halve the number of men dying from prostate cancer.
We'll also halve the number of men facing serious ongoing side effects from prostate cancer treatment.
“I'd like to imagine my son growing up in a world where prostate cancer can be cured. In a world where the way Dad freely talked about his health and his regular health checks isn’t unique, but the norm.”
Cancer research and care is full of difficult problems, but we’ve never been afraid of a challenge. We’ve spent years funding the most innovative and forward-thinking projects, getting the best researchers together to tackle the thorniest issues.
We’re focused on what works for men. From early detection through to diagnosis, treatment, and support: we’re not just looking for a cure. We’re looking for quality of life.
The plan of attack
1. Taking action early
Helping men know the signs, symptoms and risk factors for prostate cancer.
2. Bright minds brought together
We’re bringing the best minds from around the world together to collaborate.
3. Tackling biology
Increasing the knowledge of the most lethal prostate cancer tumours, and how to slow or stop its progression.
4. Reducing side effects
No matter where they are in the world, men and their families and carers must have access to services and support.
5. Affordable treatment
We’re influencing governments to provide affordable treatment and to get new treatments into practice faster.
6. Tailored treatments, precision care
Personalised treatment is the new frontier of cancer research. From distinguishing between harmless and lethal cancers, to taking into account genes, lifestyle and environment: it means a better outcome for men.
7. Helping men make tough choices
Men need the right info to understand their diagnosis and make an informed decision when it comes to treatment.
8. Raising the standard
We’re identifying excellence in prostate cancer treatment and care, to reduce the number of men who aren’t getting the best outcome possible.
9. Global initiatives
Our three largest investments in prostate cancer are global programs that will mean better outcomes for men everywhere.
We’ve funded more than 1,200 men’s health projects, in the UK and around the world. Here’s a snapshot of our work in prostate cancer.
Projects that span the globe
We link up researchers around the world and get results faster by encouraging collaboration. We share our successes and our failures, so the scientific community doesn’t waste time on duplicate research.
Global Action Plan
Our Global Action Plan (GAP) is an international research initiative that brings researchers together to tackle the toughest challenges in prostate and testicular cancer. Since GAP launched in 2011, it has formed 7 large-scale global initiatives supporting 350 researchers from 90 institutions across 21 countries.
TrueNTH is a revolutionary global care program that helps men living with prostate cancer to access care and support that improves quality of life before, during and after treatment. It focuses on empowering men to make informed decisions when it comes to treatment and side effects. TrueNTH operates across 6 countries with a team of more than 80 collaborators.
Our Prostate Cancer Outcomes (PCO) initiatives are transforming prostate cancer healthcare globally by building a better understanding of men’s experiences. By compiling reports from both doctors and patients throughout treatment and comparing this across regions, we’re forming a new benchmark for prostate cancer care. This program is working in 7 countries, with 40 collaborators and researchers.
Prostate cancer research breakthrough
Movember Foundation funded research has discovered that men have a genetic “fingerprint” within their prostate cancer cells which will help build a more tailored treatment plan for men. This will help avoid overtreatment and side effects.
In addition to large-scale efforts that span the globe, we’re also making strides for men in the UK, in partnership with Prostate Cancer UK.
Movember Centres of Excellence
In 2014, we proudly announced the opening of two inaugural Movember Centres of Excellence in partnership with Prostate Cancer UK. The centres are the first of their kind specialising in prostate cancer research with one centre involving Belfast and Manchester institutions, and the other focused in the London area. They bring experts together in an unprecedented collaboration to help accelerate research outcomes; improving the lives of men diagnosed with prostate cancer. This also provide a world-class training ground for the scientists of the future, building a legacy of top prostate cancer researchers in the UK.
The first ever ‘ManVan’ in partnership with Prostate Cancer UK and leading Welsh cancer charity Tenovus was launched in February 2014. The ManVan brings much-needed advice and support to men affected by prostate or testicular cancer in areas where such services are currently lacking. It offers one-to-one counselling, couples’ counselling, group support and benefits advice to men all over Wales.
The Movember Foundation has funded over £2 million to researchers and clinicians at institutions up and down the UK, from Glasgow to London, from Nottingham to Southampton working with our official men’s health partner Prostate Cancer UK. This will help researchers bring innovative ideas and promising projects into the field of prostate cancer research.
The National Prostate Cancer Patient Reported Outcome Measure (PROMS) is a survey of all men diagnosed with Prostate Cancer across the UK from 2015. The survey aims to understand more about the journey of a man with Prostate Cancer and then make recommendations on how health services can adapt to improve a mans health and wellbeing as well as influence policy. The survey (PROMS) will be delivered in partnership with Prostate Cancer UK, Leeds University and Queens University, Belfast.
We’re already seeing results, but there’s still work to be done.
We’ve pushed prostate cancer research forward 50 years, but there’s so much yet to be done. Men are still facing life or death questions, invasive treatments, and serious side effects. They’re dying too young.
To get to where we want to be by 2030,
we need your help.